Drug Trial Radar · NCT06459063
Intra-articular Allocetra in Osteoarthritis of the 1st Carpo-metacarpal Joint
Last checked: Nov 19, 2026Latest source record: Apr 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
46
Planned (sponsor's estimate)
Start
Jun 10, 2024
Primary completion
Sep 2026
Study completion Jan 2027
Sponsor
- Lead sponsor
- Kaplan Medical CenterAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Jun 14, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 40 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is a single center trial to assess the safety and efficacy of intra-articular administration of Allocetra to patients with 1st CMC thumb joint osteoarthritis (OA).
Conditions
- Osteoarthritis Thumb
Interventions
Allocetra - Safety run-in phaseDrug
Intra-articular injection of Allocetra performed once on Day 1 of the study at different doses.
PlaceboOther
Intra-articular injection of placebo solution containing all excipients except for the Allocetra cells.
Allocetra - Randomization phaseDrug
Intra-articular injection of selected dose of Allocetra based on the safety run-in, performed on Day 1 of the study.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Injection-related reactionsTime frame: Day 0 (Treatment visit).
- Treatment emergent adverse eventsTime frame: Day 0 to 6 months.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Kaplan Medical Center
Rehovot, Israel
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.